News

Researchers have discovered elevated expression of sFRP1, a WNT signaling inhibitor, in glaucomatous trabecular meshwork (TM) cells. They also observed that the TM has a functional signaling pathway in which elevated sFRP1 decreased outflow facility, according to one researcher.

Long-term daily supplementation with folic acid and vitamins B6 and B12 may reduce the risk of developing age-related macular degeneration (AMD) in women with established cardiovascular disease (CVD) or CVD risk factors, said William G. Christen, ScD, DO, associate professor in medicine, Harvard Medical School, and associate epidemiologist, Division of Preventive Medicine, Brigham and Women's Hospital, Boston.

Americans turning 50 today have half their lives in front of them, but without a transformation of our health-care system, their medical care and that of younger generations will not be what they have come to expect, suggested William D. Novelli, chief executive officer of the AARP, during a keynote session Sunday night.

Accommodation is the result of changes in the optical power of the crystalline lens that results from change in the lens anterior and posterior surface curvatures and thickness. The ciliary muscle is the engine that drives the accommodative process, and the lens capsule and the lens are important components of accommodation, according to Adrian Glasser, MD, from the College of Optometry, University of Houston, Houston.

A 3-month regimen of topical treatment with cyclosporine ophthalmic emulsion 0.05% (Restasis, Allergan) administered pre- and postoperatively significantly improves visual outcomes in cataract surgery patients with a multifocal IOL implanted, reported Eric D. Donnenfeld, MD, a private practitioner in Rockville Centre, NY.

Ultra high-speed optical coherence tomography (OCT) offers the potential to follow minute changes in patients with various pathologies. Johannes de Boer, PhD, the Wellman Center of Photomedicine, Harvard Medical School, Massachusetts General Hospital, Boston, reviewed the principles of OCT and the status of ultra high-speed OCT.

Second-harmonic signaling with the femtosecond laser (IntraLase, Advanced Medical Optics) can be used to probe corneal structure and function. In combination with laser-induced optical breakdown, it also can help create three-dimensional measures of elasticity as well as provide details on the biomechanical properties of the eye, according to James V. Jester, PhD, professor of ophthalmology, University of California, Irvine.

Mitochondrial oxidative stress induced by translocation of inducible nitric oxide synthetase (iNOS) from the cytosol into the photoreceptor mitochondria appears to be a primary event leading to photoreceptor damage in experimental autoimmune uveitis (EAU), said Narsing A. Rao, MD, professor of ophthalmology, and director, ophthalmic pathology laboratory and uveitis service, University of Southern California, Los Angeles.

Optical coherence tomography (OCT) continues to evolve and improve, offering clinicians more detailed information on the status of patients' eyes. Joel Shuman, MD, University of Pennsylvania Medical Center Eye Center, University of Pittsburgh School of Medicine, and a co-inventor of OCT, reviewed the technology and contrasted the first-generation technology with spectral domain technology.

The "perfect storm" in health care is on its way, according to Paul Lee, MD, JD, Duke University, Durham, NC, as he described areas where research and potential paradigm changes can contribute to meeting society's needs to enhance vision, maintain wellness, and prevent vision loss. Dr. Lee delivered a keynote address entitled "Future challenges and opportunities in eye research and the aging population" during The Association for Research in Vision and Ophthalmology (ARVO)/Alcon keynote session Sunday evening.

There is value in studying a model of human disease that is not a carbon copy, said Jayakrishna Ambati, MD, associate professor, School of Medicine, and vice chairman, Department of Ophthalmology and Visual Sciences, University of Kentucky, Lexington.

Epi-LASIK is safer for patients; it offers a lower risk of ectasia, fewer serious complications and better contrast sensitivity, according to Robert J. Mitchell.

In December 2006, the Swiss city of Geneva played host to the very first European glaucoma resident's course, designed for ophthalmic residents seeking the necessary skills for the diagnosis and therapy of glaucoma.

Welcome to this, the glaucoma special issue of Ophthalmology Times Europe. This month we aim to give you a taste of events from the International Glaucoma Society meeting, which was held in Athens in March. If you were not able to make it, we hope this section will allow you to feel as though you did not miss out on some of the important presentations.

Athens played host to the sixth annual International Glaucoma Society (IGS) congress, which ran from 28-31 March. Attended by more than 2,650 participants from around the world, the meeting earned the title of the most attended international glaucoma meeting ever held.

Bausch & Lomb has received new technology intraocular lens (NTIOL) status for the regular and violet-filtering models of its SofPort Advanced Optics intraocular lenses (IOLs).

Optometrists display a good ability to correctly identify and manage patients in busy accident and emergency (A&E) departments, according to a report published in the April issue of the British Journal of Ophthalmology.

The growing popularity of LASIK and other new innovations in refractive surgery is set to push sales in the global market from $1.3 billion in 2006 to an estimated $4.5 billion in 2009, according to market research firm Kalorama Information.

The FDA has denied Eli Lilly's appeal of the agency's ruling requiring it to conduct an additional three-year study of ruboxistaurin mesylate (Arxxant) before it can be approved for treating diabetic retinopathy (DR).

The growing popularity of LASIK and other new innovations in refractive surgery is set to push sales in the global market from $1.3 billion in 2006 to an estimated $4.5 billion in 2009, according to market research firm Kalorama Information.

Potentia Pharmaceuticals has announced that it is entering the clinical phase of development for POT-4, its lead drug candidate for the treatment of age-related macular degeneration (AMD).

The Ziemer group is to assume all worldwide marketing, sales and support duties for AMO's Amadeus II automated microkeratome.